Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2019

Feb 12, 2020

SELL
$1.33 - $5.93 $40,033 - $178,493
-30,100 Closed
0 $0
Q3 2019

Nov 12, 2019

BUY
$5.12 - $7.21 $22,016 - $31,003
4,300 Added 16.67%
30,100 $154,000
Q2 2019

Aug 12, 2019

BUY
$6.05 - $13.66 $156,090 - $352,428
25,800 New
25,800 $185,000

Others Institutions Holding CBAY

About CymaBay Therapeutics, Inc.


  • Ticker CBAY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 84,677,904
  • Description
  • CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...
More about CBAY
Track This Portfolio

Track Alpha Crest Capital Management LLC Portfolio

Follow Alpha Crest Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Alpha Crest Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Alpha Crest Capital Management LLC with notifications on news.